Blood substitute products maker Northfield Laboratories Inc. said Wednesday its fiscal second-quarter loss widened as costs increased.

The development-stage company is not yet profitable and does not have a revenue stream.

Northfield posted a loss of $7.6 million, or 28 cents per share, compared with a loss of $6.3 million, or 23 cents per share, last year. The company's fiscal year ends May 31.

Costs rose 18 percent to $8.3 million from $7 million, previously.

At the end of the quarter, the company had $56.2 million in shareholders' equity, with $51.6 million in cash and marketable securities.

Shares of Northfield rose a penny to $4.07 on the Nasdaq in morning trading.